상세 보기
초록
This study was conducted to analyze cost-effectiveness of neoadjuvant chemotherapy for locally advanced head and neck cancer in Korean healthcare setting. We constructed a decision analytical model to estimate total costs and outcomes of paclitaxel+cisplatin (PC) or docetaxel+cisplatin+5-FU (DCF) for 2 years time horizon in 100 patient cohort with locally advanced head and neck cancer. Base analysis showed that cost savings of PC regimen were 379 million Korean Won and 231 million Korean Won in societal and payer's perspectives, respectively, compared to DCF regimen,and life saved was 0.18. PC regimen as a dominant strategy was found to be robust through sensitivity analyses.
키워드
cost-effectiveness; neoadjuvant chemotherapy; head and neck cancer; paclitaxel; docetaxel; cisplatin; 5-FU
- 제목
- 국소진행성 두경부암에서 선행항암화학요법제로 사용되는 Paclitaxel과 Cisplatin 병용요법의 비용-효과성
- 제목 (타언어)
- Cost-Effectiveness of Paclitaxel plus Cisplatin as a Neoadjuvant Chemotherapy for Locally Advanced Head and Neck Cancer
- 저자
- 손현순; 이태진
- 발행일
- 2010-06
- 저널명
- 한국임상약학회지
- 권
- 20
- 호
- 1
- 페이지
- 30 ~ 38